X0306 4 2021-06-21 1 0001840574 Verve Therapeutics, Inc. VERV 0001823061 Casdin Private Growth Equity Fund, L.P. 1350 AVENUE OF THE AMERICAS, SUITE 2600 NEW YORK NY 10019 0 0 1 0 Common Stock 2021-06-21 4 C 0 620571 A 620571 D Series B Preferred Stock 2021-06-21 4 C 0 5746183 D Common Stock 620571 0 D The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. /s/ Eli Casdin, Managing Member of the General Partner of Casdin Private Growth Equity Fund, L.P. 2021-06-22